Clinical Trial Update: Study of Safety and Efficacy of TC011 in the Relapsed/Refractory Large B Cell Non-Hodgkin Lymphoma Patients [Phase 1, Phase 2]

View source ↗

Summary

This clinical trial update describes a Phase 1/2 study of TC011 for relapsed/refractory large B-cell non-Hodgkin lymphoma, assessing safety and efficacy, which …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Large B-cell Lymphoma
• High-grade B-cell Lymphoma
• Mediastinal Large B-cell Lymphoma
• Transformed Follicular Lymphoma

Drugs mentioned

• TC011

Snippet

Sponsor: TICAROS Co., Ltd. | Conditions: Relapsed Large B-cell Lymphoma, Refractory Large B-cell Lymphoma | Phase 1, Phase 2 | Status: RECRUITING